Supplementary Table 1. Baseline characteristics of study participants according to treatment group (full analysis set)

|  |  |  |  |
| --- | --- | --- | --- |
|  | Cilostazol | Aspirin | p-value |
| N | 58 | 56 |  |
| Age (years) | 59.8±6.8 | 60.1±6.3 | 0.81 |
| Sex (male, %) | 43 (74.1%) | 33 (58.9%) | 0.112 |
| Height (cm) | 166±8 | 164±7 | 0.162 |
| Weight (kg) | 69±9 | 67±12 | 0.243 |
| Smoking, n (%) | 15 (25.9%) | 7 (12.5%) | 0.097 |
| Non-drinkers, n (%) | 41 (70.7%) | 41 (73.2%) | 0.836 |
| Waist circumference (cm) | 90±8 | 88±10 | 0.212 |
| Systolic blood pressure (mmHg) | 126±14 | 128±16 | 0.411 |
| Diastolic blood pressure (mmHg) | 76±11 | 76±11 | 0.704 |
| Heart rate (bpm) | 75±11 | 78±11 | 0.183 |
| Previous cilostazol exposure, n (%) | 7 (12.1%) | 6 (10.7%) | 1 |
| History of cardiovascular disease, n (%) | 4 (6.9%) | 4 (7.1%) | 1 |
| Hypertension, n (%) | 28 (48.3%) | 29 (51.8%) | 0.852 |
| Dyslipidemia, n (%) | 51 (87.9%) | 49 (87.5%) | 1 |
| Albuminuria, n (%) | 0 | 0 |  |
| White blood cells (x103/mm3) | 6.13±1.47 | 6.55±1.57 | 0.143 |
| Hemoglobin (g/dL) | 14.4±1.5 | 13.9±1.5 | 0.063 |
| Platelet count (x103/μL) | 226±63 | 229±60 | 0.752 |
| Fasting glucose (mg/dL) | 132±29 | 146±42 | 0.04 |
| HbA1c (%) | 7.0±1.3 | 7.3±1.3 | 0.199 |
| Fasting insulin (μIU/mL) | 8.53±3.86 | 9.76±9.51 | 0.375 |
| HOMA-IR | 2.82±1.49 | 3.55±3.42 | 0.145 |
| HOMA-β (%) | 50.3±25.4 | 53.0±68.3 | 0.782 |
| Total cholesterol (mg/dL) | 140±41 | 140±33 | 0.97 |
| Triglycerides (mg/dL) | 120±65 | 151±77 | 0.024 |
| HDL cholesterol (mg/dL) | 52±11 | 52±19 | 0.98 |
| LDL cholesterol (mg/dL) | 83±38 | 79±30 | 0.457 |
| Blood urea nitrogen (mg/dL) | 14.9±3.5 | 16.1±5.4 | 0.16 |
| Serum creatinine (mg/dL) | 1.43±4.75 | 1.49±4.97 | 0.947 |
| eGFR (mL/min/1.73 m2) | 92.7±10.9 | 88.8±16.8 | 0.146 |
| AST (IU/L) | 24.±8 | 25±12 | 0.519 |
| ALT (IU/L) | 25±13 | 24±14 | 0.946 |
| VerifyNow (ARU) | 623±61 | 637±40 | 0.696 |
| PFA-100 (sec) | 137±41 | 140±50 | 0.754 |
| CRP (ng/mL) | 1271±4319 | 868±1368 | 0.501 |
| CD40 ligand (pg/mL) | 1880±1470 | 1703±1624 | 0.541 |
| Diabetes medication |  |  |  |
| Metformin, n (%) | 39 (67.2%) | 44 (78.6%) | 0.209 |
| Sulfonylurea, n (%) | 13 (22.4%) | 23 (41.1%) | 0.044 |
| Thiazolidinedione, n (%) | 4 (6.9%) | 5 (8.9%) | 0.74 |
| DPP-4 inhibitor, n (%) | 32 (55.2%) | 37 (66.1%) | 0.256 |
| SGLT2 inhibitor, n (%) | 13 (22.4%) | 10 (17.9%) | 0.643 |
| Hypertension medication, n (%) | 25 (43.1%) | 24 (42.9%) | 1 |
| Angiotensin II receptor blocker, n (%) | 20 (34.5%) | 14 (25.0%) | 0.31 |
| ACE inhibitor, n (%) | 1 (1.7%) | 2 (3.6%) | 0.615 |
| Diuretics, n (%) | 0 (0%) | 1 (1.8%) | 0.491 |
| Calcium channel blockers, n (%) | 6 (10.3%) | 7 (12.5%) | 0.775 |
| β-blocker, n (%) | 2 (3.4%) | 2 (3.6%) | 1 |
| Other hypertension medication, n (%) | 3 (5.2%) | 4 (7.1%) | 0.741 |
| Dyslipidemia medication, n (%) | 53 (91.4%) | 53 (94.6%) | 0.717 |
| Statin, n (%) | 51 (87.9%) | 53 (94.6%) | 0.322 |
| Fibrate, n (%) | 2 (3.4%) | 2 (3.6%) | 1 |
| Other dyslipidemia medication, n (%) | 6 (10.3%) | 6 (10.7%) | 1 |

Abbreviations: ACE, angiotensin-converting-enzyme; ALT, alanine transaminase; AST, aspartate transferase; CD40, cluster of differentiation 40; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; SGLT-2, sodium-glucose cotransporter-2.

Supplementary table 2. Baseline characteristics of study participants according to treatment group (per protocol set)

|  |  |  |  |
| --- | --- | --- | --- |
|  | Cilostazol | Aspirin | p-value |
| N | 37 | 53 |  |
| Age (years) | 61±7 | 60±6 | 0.501 |
| Sex (male, %) | 29 (78.4%) | 30 (56.6%) | 0.043 |
| Height (cm) | 166±8 | 163±7 | 0.088 |
| Weight (kg) | 68±9 | 66±12 | 0.322 |
| Smoking, n (%) | 11 (29.7%) | 7 (13.2%) | 0.065 |
| Non-drinkers, n (%) | 19 (51.4%) | 17 (32.1%) | 0.082 |
| Waist circumference (cm) | 90±8 | 88±10 | 0.328 |
| Systolic blood pressure (mmHg) | 129±13 | 128±16 | 0.713 |
| Diastolic blood pressure (mmHg) | 79±13 | 75±11 | 0.201 |
| Heart rate (bpm) | 74±12 | 78±11 | 0.131 |
| Previous cilostazol exposure, n (%) | 7 (18.9%) | 6 (11.3%) | 0.369 |
| History of cardiovascular disease, n (%) | 4 (10.8%) | 3 (5.7%) | 0.44 |
| Hypertension, n (%) | 22 (59.5%) | 28 (52.8%) | 0.667 |
| Dyslipidemia, n (%) | 32 (86.5%) | 46 (86.8%) | 1 |
| Albuminuria, n (%) | 0 | 0 |  |
| White blood cells (x103/mm3) | 6.16±1.68 | 6.54±1.57 | 0.288 |
| Hemoglobin (g/dL) | 14.4±1.6 | 13.9±1.4 | 0.141 |
| Platelet count (x103/μL) | 229±65 | 233±55 | 0.748 |
| Fasting glucose (mg/dL) | 135±34 | 142±33 | 0.387 |
| HbA1c (%) | 7.2±1.6 | 7.3±1.3 | 0.629 |
| Fasting insulin (μIU/mL) | 8.2±3.8 | 9.6±9.6 | 0.351 |
| HOMA-IR | 2.78±1.43 | 3.32±3.02 | 0.261 |
| HOMA-β (%) | 48.3±26.5 | 53.8±69.4 | 0.601 |
| Total cholesterol (mg/dL) | 134±46 | 139±32 | 0.48 |
| Triglycerides (mg/dL) | 116±68 | 147±75 | 0.044 |
| HDL cholesterol (mg/dL) | 54±12 | 52±20 | 0.607 |
| LDL cholesterol (mg/dL) | 76±27 | 77±29 | 0.834 |
| Blood urea nitrogen (mg/dL) | 15±4 | 16±6 | 0.17 |
| Serum creatinine (mg/dL) | 1.80±5.94 | 1.52±5.11 | 0.812 |
| eGFR (mL/min/1.73 m2) |  |  | 0.657 |
| AST (IU/L) | 23±7 | 25±12 | 0.331 |
| ALT (IU/L) | 23±12 | 24±14 | 0.794 |
| VerifyNow (ARU) | 637±34 | 639±32 | 0.759 |
| PFA-100 (sec) | 136±46 | 138±32 | 0.832 |
| CRP (ng/mL) | 1706±5355 | 902±1417 | 0.299 |
| CD40 ligand (pg/mL) | 1992±1432 | 1747±1621 | 0.451 |
| Diabetes medication, n (%) |  |  |  |
| Metformin, n (%) | 21 (56.8%) | 41 (77.4%) | 0.063 |
| Sulfonylurea, n (%) | 9 (24.3%) | 21 (39.6%) | 0.174 |
| Thiazolidinedione, n (%) | 3(8.1%) | 5 (9.4%) | 1 |
| DPP-4 inhibitor, n (%) | 22 (59.5%) | 35 (66%) | 0.657 |
| SGLT2 inhibitor, n (%) | 8 (21.6%) | 9 (17%) | 0.596 |
| Hypertension medication, n (%) | 20 (54.1%) | 24 (45.3%) | 0.521 |
| Angiotensin II receptor blocker, n (%) | 17 (45.9%) | 14 (26.4%) | 0.072 |
| ACE inhibitor, n (%) | 0 | 2 (3.8%) | 0.51 |
| Diuretics, n (%) | 0 | 1 (1.9%) | 1 |
| Calcium channel blockers, n (%) | 4 (10.8%) | 7 (13.2%) | 1 |
| β-blocker, n (%) | 2 (5.4%) | 2 (3.8%) | 1 |
| Other hypertension medication, n (%) | 3 (8.1) | 4 (7.5%) | 1 |
| Dyslipidemia medication, n (%) | 33 (89.2%) | 50 (94.3%) | 0.444 |
| Statin, n (%) | 32 (86.5%) | 50 (94.3%) | 0.266 |
| Fibrate, n (%) | 1 (2.7%) | 2 (3.8%) | 1 |
| Other dyslipidemia medication, n (%) | 2 (5.4%) | 5 (9.4%) | 0.695 |

Supplementary figure 1. Patient selection in the current study.

A picture containing screenshot

Description automatically generated